Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

Clicks: 166
ID: 273607
2021
Although case-control analyses have suggested an additive value with the association of clarithromycin to continuous lenalidomide and dexamethasone (Rd), there are not phase III trials confirming these results. In this phase III trial, 286 patients with MM ineligible for ASCT received Rd with or wit …
Reference Key
n2021bloodlenalidomide Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Puig N;Hernández MT;Rosiñol L;González E;de Arriba F;Oriol A;González-Calle V;Escalante F;de la Rubia J;Gironella M;Ríos R;García-Sánchez R;Arguiñano JM;Alegre A;Martín J;Gutiérrez NC;Calasanz MJ;Martín ML;Couto MDC;Casanova M;Arnao M;Pérez-Persona E;Garzón S;González MS;Martín-Sánchez G;Ocio EM;Coleman M;Encinas C;Vale AM;Teruel AI;Cortés-Rodríguez M;Paiva B;Cedena MT;San-Miguel JF;Lahuerta JJ;Bladé J;Niesvizky R;Mateos MV;;
Journal blood cancer journal
Year 2021
DOI DOI not found
URL
https://www.pubmed.gov/34021118/
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE pubmed abstract nih national institutes of health national library of medicine pmid:34021118 pmc8139975 doi:10.1038/s41408-021-00490-8 noemi puig miguel t hernández maría-victoria mateos

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.